Papillary tumor of the pineal region (PTPR) is a recently described tumor entity thought to arise from the specialized ependyma of the subcommissural organ. Whereas histologic features of PTPR are well defined, data on the prognostic value of PTPR remain scarce. We therefore investigated clinicopathologic features, including data on progression-free survival and overall survival, in a retrospective series of 31 PTPR. The age of the 14 males and 17 females ranged from 5 to 66 years (median age, 29 years). Histologically, all tumors were characterized by an epithelial-like growth pattern in which the vessels were covered by layers of columnar or cuboidal tumor cells forming perivascular pseudorosettes. Most of the tumor cells showed strong expression of neuron-specific enolase, cytokeratins (particularly CK18), S-100 protein, and vimentin. Most PTPRs examined also expressed microtubule-associated protein-2. Expression of synaptophysin, epithelial membrane antigen, transthyretin, neural cell adhesion molecule, and nestin was encountered in some tumors. Gross total resection could be achieved in 21 of 31 cases; 15 patients received radiotherapy on resection of the primary tumor. Nevertheless, the majority of patients experienced recurrences; 5-year estimates for overall survival and progression-free survival were 73% and 27%, respectively. To conclude, the clinical course of PTPR is characterized by frequent local recurrence, and the value of radiotherapy on disease progression will need to be investigated in future prospective trials.
INTRODUCTION
Neuroepithelial papillary tumor of the pineal region (PTPR) is a recently described entity (1) thought to arise from the specialized ependyma of the subcommissural organ (1Y4). This tumor shares morphologic features with both papillary ependymoma and choroid plexus tumors. PTPR is characterized by an epithelial-like growth pattern in which the vessels are covered by layers of tumor cells forming perivascular pseudorosettes and their immunohistochemical profile is very similar to that of choroid plexus tumors (1, 4) . As a result of the rarity of these tumors, data on the prognostic value of PTPR remain scarce. We therefore investigated clinical and histopathologic features in a retrospective series of 31 patients harboring PTPR to better define the prognosis of this newly described entity.
MATERIALS AND METHODS

Patients
Samples from PTPRs of 31 patients obtained between 1979 and 2005 were included in this study. These PTPRs had been initially diagnosed as pineal parenchymal tumors, ependymomas, papillary meningiomas, or choroid plexus tumors at 12 centers in France (CHU Clermont Ferrand; Hôpital Henri Mondor, Créteil; Hôpital Neurologique, Lyon; CHU La Timone, Marseille; CHU Nancy; Hôpital Pasteur, Nice; CHR Orléans; Hôpital Lariboisière, Hôpital SainteAnne, Hôpital Bichat, Paris; CHU Poitiers; and CHU Rangueil, Toulouse) and 3 centers in Germany (University Hospitals of Münster, Giessen, and Essen). All cases were reviewed and diagnosed as PTPR according to histologic criteria described previously (1) . Clinical data were obtained by chart review and review of neuroradiologic imaging studies. Furthermore, neurosurgeons and general practitioners involved in the care of the patients were contacted to obtain information on progression-free survival and overall survival.
were counted in 10 randomly selected fields at high magnification (400Â) and expressed as the number in 10 high-power fields (HPF = 0.159 mm 2 ). Sections were also stained with periodic acid Schiff reagent before and after amylase digestion. Immunohistochemical staining was performed using the avidin biotin technique and antibodies against human S-100 protein (S100-P), neuron-specific enolase, synaptophysin, neurofilament (70-and 270-kD isoforms), chromogranin A, cytokeratin (CK) (several CKs recognized by antibody KL1; CK18, CK20, CK7, and CK5/6), vimentin, glial fibrillary acid protein (GFAP), epithelial membrane antigen, transthyretin (TTR), E-cadherin (E-Cad), neural cell adhesion molecule (NCAM), Ki67, microtubule-associated protein-2 (MAP-2), or Kir7.1 (5) . The number of tumors analyzed using each antibody is shown in Table 1 . After incubation with primary antibodies (incubation time 2 hours to overnight at room temperature), bound antibodies were detected using biotinylated secondary antibodies and streptavidin peroxidase complex (DAKO, Trappes, France), the color reaction being developed with 3,3-diaminobenzidine or 3 amino 9 ethyl carbazole. The intensity of labeling was scored as 0 when absent or very low, T when weak, or + when strong. Ki67 index was evaluated by counting the number of labeled tumor cells out of 500 cells.
Statistical Analysis
Probabilities of overall survival and progression-free survival were estimated using the Kaplan-Meier method (6).
The effect of clinical variables age, sex, tumor size, gross total resection, and adjuvant radiotherapy on the probability of overall survival and progression-free survival was investigated on univariate analysis using the log-rank test. To this end, data on age and tumor size were dichotomized according to median values into younger age (G30 years) and older age (Q30 years), smaller tumor size (G30 mm) and larger tumor size (Q30 mm), as well as the presence or absence of mitotic activity (Q1 mitosis/10 HPF) or marked mitotic activity (Q5 mitoses/10 HPF).
RESULTS
Clinical Data
The main clinical data are summarized in Table 2 . The patients_ ages ranged from 5 to 66 years (median age, 29 years) with a mean age of 31.5 T 2.6 years (mean T standard error of mean [SEM] ). A slight predominance of females was observed (14 male vs 17 female patients). Tumor size (maximal diameter as assessed on preoperative imaging studies or intraoperatively) accounted for 29.3 T 2.2 mm (mean T SEM, n = 24). Gross total resection of the tumor could be achieved in 21 patients. In the remaining cases, only incomplete resection of the tumor was feasible (n = 6) or surgery remained restricted to a diagnostic biopsy (n = 4). Fifteen patients received heterogenous radiotherapy regimens after complete (n = 9) or incomplete (n = 6) resection of the primary tumor. 
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Histopathological Features
The histopathologic features of cases 1 through 6 and 24 through 31 have been described previously (1, 4, 7) . In 5 cases (cases 1, 7, 10, 11, and 17), the papillary tumor was contiguous with the normal pineal parenchyma. All the tumors presented an epithelial-like growth pattern in which the vessels were covered by layers of columnar or cuboidal tumoral cells.
Large areas with papillary features were present in 13 tumors (Fig. 1A, B ) and 9 tumors presented more diffuse areas with fewer papillary features (Fig. 1C) . Perivascular pseudorosettes, true rosettes, or tubes around small lumina were also present. Mixed ependymal and papillary features were seen in some tumors. The tumor cells, which were sometimes vacuolated, frequently presented a well-defined cytoplasmic membrane and a round or oval nucleus sometimes indented with stippled chromatin. In general, mitotic activity was moderate (median, 1 mitosis/10 HPF; range, 0Y10 mitoses/10 HPF), but 6 PTPRs displayed marked mitotic activity (Q5 mitoses/10 HPF). Necrotic areas were observed in almost all tumors. No vascular proliferation was observed, but vessels often displayed slight endothelial hyperplasia or hyalinization. Nine of 10 tumors analyzed showed amylase-resistant periodic acid Schiff staining. The recurrences had the same morphologic features as the corresponding primary tumors but often displayed more papillary features.
The immunohistochemical results are reported in Table  1 . Reactivity with the broad-spectrum anti-CK antibody KL1 was seen in all 30 tumors analyzed. Staining was more intense in areas containing papillary structures (Fig. 1D ) than in the diffuse areas with fewer papillary features in which staining was focal. All 11 tumors tested for CK18 immunoreactivity showed intense staining (Fig. 1E) . No CK20 staining was seen in the 6 tumors analyzed. In the 7 tested tumors, slight staining for CK7 or CK5/6 was seen in 2 or 1, respectively. Epithelial membrane antigen staining was present in 25 of 31 tumors but was restricted to the cell surface, particularly on the pole facing the vessels. No neurofilament immunolabeling was seen, whereas the neuroendocrine marker, neuron-specific enolase, was seen in all 17 tumors analyzed. Synaptophysin and chromogranin A were sometimes focally and slightly expressed. Cytoplasmic, and often additional nuclear, S100-P labeling of nearly all tumor cells (Fig. 1K ) was seen in 92% of the 24 tumors tested. Many tumor cells were vimentin-positive, usually with staining of the paranuclear cytoplasm adjacent to vessel walls. Only focal immunostaining for GFAP was seen in 12% of the 25 tumors tested, but GFAP expression was noticed in perivascular areas at the periphery of the tumors or in scattered reactive cells. Focal TTR staining was seen in 3 of the 6 tumors tested and this protein was also present in pineal cells adjacent to the tumor (Fig. 1F) . NCAM and E-cadherin expression was analyzed in 2 tumors. Tumor cells expressed NCAM, particularly on their surface membrane (Fig. 1H ), but did not express E-cadherin (Fig. 1I) ; these 2 tumors also expressed nestin (Fig. 1G) . In 11 of 14 tumors, Kir7.1 was not expressed and distinct membranous staining was only seen in 3 tumors, as reported previously (4). Distinct MAP-2 staining was seen in 13 of 15 PTPRs examined (Fig. 1J) . The Ki67 proliferation index as determined in 14 tumors was lower than 5% in 5, 5% to 10% in 5, and higher than 10% in 4 (Fig. 1L) (Fig. 2) . Gross total resection was the only clinical factor that tended to be associated with overall survival and recurrence (p = 0.10 and p = 0.16, respectively), but the correlation failed to achieve statistical significance. The presence of mitotic activity (Q1 mitosis/10 HPF) did not affect overall survival or progression-free survival. Resection and/or radiotherapy of the secondary tumors were often performed and in some cases associated with stabilization of tumor progression.
DISCUSSION
The present study represents the largest series of PTPR reported thus far and is the first to systematically address prognosis of this newly evolving tumor entity. Originally described in 2003 (1), PTPR has been well recognized by other authors (2, 4, 7Y9). All PTPR of the present series showed the salient histologic features of PTPR, that is, loose papillary and more dense cellular areas exhibiting pseudorosettes, true rosettes, or tubes, necrosis, and, sometimes, vacuolated tumor cells. Because the differential diagnosis of PTPR includes papillary pineocytomas and other pineal parenchymal tumors (10Y12), papillary ependymomas (13), metastasis (14) , and choroid plexus tumors (15, 16) , further characterization of the immunohistologic profile of PTPR is clearly of importance. In line with previous observations (1, 2, 4, 7) , the PTPR of the present series generally expressed CK, neuron-specific enolase, S100-P, vimentin, and, sometimes, epithelial membrane antigen. Because CK7 and CK20 expression was absent or very low, this finding may be useful in differentiating PTPR from metastatic carcinomas, which express CK7 and/or CK20 (17) . Moreover, CK18 was highly expressed in agreement with the high levels of transcripts for this protein found in 2 PTPRs by microarray (18) . Moreover, because CK18 expression is also present in the ependymal cells arising from the subcommissural organ (SCO) (19) , this observation might also further point toward an origin of PTPR from this organ. The focal expression of TTR seen in some of the PTPR examined is in agreement with the expression of TTR in PTPR recently demonstrated by microarray analysis and real-time reverse transcriptaseYpolymerase chain reaction (18) and also corresponds to TTR expression in the bovine SCO (20) .
Because cytokeratins and TTR are also expressed in choroid plexus tumors (21) , the immunohistochemical profile of PTPR shares similarities to that of choroid plexus tumors.
However, most PTPRs do not express Kir7.1, which is frequently encountered in choroid plexus tumors (4). Moreover, the presence of MAP-2 in PTPR and its absence in choroid plexus tumors may also aid the distinction of PTPR from choroid plexus tumors (4). Epithelial membrane antigen labeling, seen in some cases, resembled the dot and ring pattern encountered in ependymomas (22) , suggesting the ependymal differentiation of PTPRs. The high expression of NCAM, also reported by Shibahara et al (2) , and the absence of E-cadherin labeling in 2 tumors analyzed in our series also favor an ependymal origin of PTPR, because ependymal cells and ependymomas usually do not express E-cadherin but strongly display NCAM expression (23) . The differential expression of NCAM and E-cadherin in PTPR and choroid plexus tumors may be additional criteria of diagnosis. Nestin expression, found in ependymomas (24, 25) and ependymocytes of the SCO (26), might also be useful in the diagnosis of PTPR, because nestin immunoreactivity is usually not observed in metastases (27) .
In line with previous observations, mitotic activity and Ki67 proliferation indices in PTPR were moderate (2, 7) . In the present series, mitotic activity was not significantly associated with a worse prognosis. Of note, Ki67 proliferation indices in PTPR were comparable to that described in intracranial ependymomas (28) and represent an independent prognostic factor in the latter (29) . Because homogenously processed material for Ki67/MIB1 staining was not available from all our cases, however, the precise relationship between proliferation index and patient outcome in PTPR remains to be determined in future prospective trials. The observation that high Ki67 indices were observed in some younger patients might well point toward a more aggressive biologic behavior in this age group. However, our data also suggest that younger age (G30 years) per se is not associated with a higher probability of tumor progression or death.
The clinical behavior of PTPR is characterized by frequent local recurrence, as reported in the literature for intracranial ependymomas (30) , and spinal dissemination seems to be rare. Indeed, probability for progression-free survival in the present series was lower than that reported for intracranial ependymomas in the third ventricle in adult patients (31) .
As a result of the relatively small number of cases, multivariate analysis of survival data was not deemed feasible. On univariate analysis, gross total resection was the only clinical factor that tended to be associated with overall survival and recurrence, but statistical significance was not achieved. This essentially negative result is almost certainly related to the retrospective nature of our study, which involved different treatment approaches at the various centers (especially radiotherapy regimens were rather heterogenous) and has therefore to be interpreted with caution. As shown for spinal cord ependymomas, radiotherapy might well stabilize evolution of ependymal tumors and reirradiation may be the treatment of choice for patients with a recurrence after incomplete resection or when surgery cannot be performed (32) .
In conclusion, the clinical course of PTPR is characterized by frequent local recurrence. The value of radiotherapy on disease progression in PTPR will need to be investigated in a future prospective trial, which will also provide data on long-term follow up and may further aid the identification of histopathologic factors possibly associated with prognosis in PTPR.
